Evaluation of Treatment and Other Factors That Lead to Drug Court Success,Substance Use Reduction,and Mental Health Symptomatology Reduction Over Time

Abstract

Adults presenting with substance use and mental health disorders in the criminal justice system is well documented. While studies have examined drug courts and medication-assisted treatment (MAT), few have examined social and behavioral health indicators, and even fewer have multiple study periods. This study employed a comprehensive approach to studying the MAT contribution to drug court success; reduce substance use, mental health symptoms, and risky behaviors; and the role that violence or trauma plays in mental health symptomatology. Using three time points, our findings indicated that MAT did not play a significant role in the reduction of substance use, risky behaviors, or mental health symptoms or increasing the odds of successful court graduation. However, there was an overall improvement from intake to termination in reduction of substance use, risky behaviors, and mental health symptomatology. Other factors, including social support, may play a role in drug court graduation. Policy implications are discussed.

Keywords

drug court substance use mental health symptomatology trauma medication assisted treatment

Get full access to this article

View all access options for this article.

References

Abuse

(2013). Mental Health Services Administration: Einstein expert panel: Medication-assisted treatment and the criminal justice system. Rockville, MD: Department of Health and Human Services (Substance abuse and mental health services administration, center for substance abuse treatment).

Becker

W. C.

Sullivan

L. E.

Tetrault

J. M.

Desai

R. A.

Fiellin

D. A.

(2008). Non-medical use, abuse and dependence on prescription opioids among US adults: Psychiatric, medical and substance use correlates. Drug and Alcohol Dependence, 94, 38-47.

Belenko

(1998). Research on drug courts: A critical review. National Drug Court Institute Review, 1, 1-42.

Belenko

(2001). Research on drug courts: A critical review 2001 update. National Center on Addiction and Substance Abuse at Columbia University (CASA), 5-60.

Benotsch

E. G.

Koester

Luckman

Martin

A. M.

Cejka

(2011). Non-medical use of prescription drugs and sexual risk behavior in young adults. Addictive Behaviors, 36, 152-155.

Binswanger

I. A.

Blatchford

P. J.

Mueller

S. R.

Stern

M. F.

(2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159, 592-600.

Britton

. (2016). Syringe Exchange Programs in Ohio. Cleveland, OH: The Center for Community Solutions.

Broz

Pham

Spiller

Wejnert

Neaigus

Paz-Bailey

(2014). Prevalence of HIV infection and risk behaviors among younger and older injecting drug users in the United States, 2009. AIDS and Behavior, 18, 284-296.

Bureau of Justice Statistics. (2016). Census of Problem-solving courts, 2012. Retrieved from https://www.bjs.gov/content/pub/pdf/cpsc12.pdf

10.

Carey

S. M.

Waller

M. S.

(2011, March). Oregon drug courts: Statewide costs and promising practices. NPC Research. Retrieved from http://npcresearch.com/publication/oregon-drug-court-cost-study-statewide-costs-and-promising-practices-final-report-3/

11.

Centers for Disease Control and Prevention. (2015). Vital Signs: Today’s Heroin Epidemic – More People at Risk, Multiple Drugs Abused. MMWR 2015.

12.

Centers for Disease Control and Prevention. (2016). Increases in drug and opioid-involved overdose deaths—United States 2010-2015. MMWR, 65, 1445-1452.

13.

Centers for Disease Control and Prevention. (2017). Deaths involving fentanyl, fentanyl analogs, and U-47700—10 States. MMWR, 66, 1197-1202.

14.

Cicero

T. J.

Ellis

M. S.

Surratt

H. L.

Kurtz

S. P.

(2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71, 821-826.

15.

Compton

W. M.

Jones

C. M.

Baldwin

G. T.

(2016). Relationship between nonmedical prescription-opioid use and heroin use. New England Journal of Medicine, 374, 154-163.

16.

Conover

W. J.

Iman

R. L.

(1982). Analysis of covariance using the rank transformation. Biometrics, 38, 715-724.

17.

Crane

E. H.

(2015, November). Emergency department visits involving narcotic pain relievers. SAMHSA: The CBHSQ Report. Retrieved from https://www.samhsa.gov/data/sites/default/files/report_2083/ShortReport-2083.html

18.

Degenhardt

Bucello

Mathers

Briegleb

Ali

Hickman

McLaren

(2011). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction, 106, 32-51.

19.

Evans

Min

Huang

Urada

Liu

Nosyk

(2015). Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-2010. Addiction, 110, 996-1005.

20.

Fuller

C. M.

Vlahov

Ompad

D. C.

Shah

Arria

Strathdee

S. A.

(2002). High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: A case-control study. Drug and Alcohol Dependence, 1, 189-198.

21.

Gallagher

J. R.

(2014). Predicting criminal recidivism following drug court: Implications for drug court practice and policy advocacy. Journal of Addictions & Offender Counseling, 35, 15-29.

22.

Gibson

D. R.

Flynn

N. M.

Perales

(2001). Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. Aids, 15, 1329-1341.

23.

Gordon

M. S.

Kinlock

T. W.

Schwartz

R. P.

Fitzgerald

T. T.

O’Grady

K. E.

Vocci

F. J.

(2014). A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry. Drug and Alcohol Dependence, 142, 33-40.

24.

Gordon

M. S.

Kinlock

T. W.

Schwartz

R. P.

O’Grady

K. E.

(2008). A randomized clinical trial of methadone maintenance for prisoners: Findings at 6 months post-release. Addiction, 103, 1333-1342.

25.

Grella

C. E.

Lovinger

(2011). 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug and Alcohol Dependence, 118, 251-258.

26.

Hser

Y. I.

Saxon

A. J.

Huang

Hasson

Thomas

Hillhouse

. . . Cohen

(2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109, 79-87.

27.

Huddleston

Marlowe

D. B.

(2011). Painting the current picture: A national report on drug courts and other problem-solving court programs in the United States. Alexandria, VA: National Drug Court Institute.

28.

Hughes

Williams

M. R.

Lipari

R. N.

Bose

(2016). Prescription drug use and misuse in the United States: Results from the 2015 national survey on drug use and health. SAMHSA: NSDUH Data Review. Retrieved from https://www.samhsa.gov/data/

29.

Johanson

C. E.

Arfken

C. L.

di Menza

Schuster

C. R.

(2012). Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug and Alcohol Dependence, 120, 190-195.

30.

Kerridge

B. T.

Saha

T. D.

Chou

S. P.

Zhang

Jung

Ruan

W. J.

Smith

Huang

Hasin

D. S.

(2015). Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions–III. Drug and alcohol dependence, 156, 47-56.

31.

Krupitsky

Zvartau

Blokhina

Verbitskaya

Wahlgren

Tsoy-Podosenin

Tyurina

(2012). Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry, 69, 973-981.

32.

Kurtz

S. P.

Surratt

H. L.

Buttram

M. E.

Levi-Minzi

M. A.

Chen

(2013). Interview as intervention: The case of young adult multidrug users in the club scene. Journal of Substance Abuse Treatment, 44, 301-308.

33.

Lake

Wood

Dong

Dobrer

Montaner

Kerr

(2015). The impact of childhood emotional abuse on violence among people who inject drugs. Drug and Alcohol Review, 34, 4-9.

34.

Lavonas

E. J.

Severtson

S. G.

Martinez

E. M.

Bucher-Bartelson

Le Lait

M. C.

Green

J. L.

. . . Surratt

H. L.

(2014). Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 47, 27-34.

35.

Mackesy-Amiti

M. E.

Boodram

Williams

Ouellet

L. J.

Broz

(2013). Sexual risk behavior associated with transition to injection among young non-injecting heroin users. AIDS and Behavior, 17, 2459-2466.

36.

Magura

Lee

J. D.

Hershberger

Joseph

Marsch

Shropshire

Rosenblum

(2009). Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug and Alcohol Dependence, 99, 222-230.

37.

Marlowe

D. B.

DeMatteo

D. S.

Festinger

D. S.

(2003). A sober assessment of Drug Courts 1. Federal Sentencing Reporter, 16, 153-157.

38.

Martin

N. K.

Hickman

Hutchinson

S. J.

Goldberg

D. J.

Vickerman

(2013). Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases, 57(Suppl. 2), S39-S45.

39.

Matusow

Dickman

S. L.

Rich

J. D.

Fong

Dumont

D. M.

Hardin

Rosenblum

(2013). Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment, 44, 473-480.

40.

Meade

C. S.

Bevilacqua

L. A.

Moore

E. D.

Griffin

M. L.

Gardin

J. G.

Potter

J. S.

. . . Weiss

R. D.

(2014). Concurrent substance abuse is associated with sexual risk behavior among adults seeking treatment for prescription opioid dependence. The American Journal on Addictions, 23, 27-33.

41.

Meade

C. S.

Weiss

R. D.

Fitzmaurice

G. M.

Poole

S. A.

Subramaniam

G. A.

Patkar

A. A.

Woody

G. E.

(2010). HIV risk behavior in treatment-seeking opioid-dependent youth: Results form a NIDA clinical trials network multi-site study. Journal of Acquired Immune Deficiency Syndrome, 55, 65-72.

42.

Mitchell

Wilson

D. B.

Eggers

MacKenzie

D. L.

(2012). Assessing the effectiveness of drug courts on recidivism: A meta-analytic review of traditional and non-traditional drug courts. Journal of Criminal Justice, 40, 60-71.

43.

Modesto-Lowe

Brooks

Petry

(2010). Methadone deaths: Risk factors in pain and addicted populations. Journal of General Internal Medicine, 25, 305-309.

44.

National Association of Drug Court Professionals. (1997). Defining drug courts: The ten key components. Retrieved from http://www.ndci.org/sites/default/files/nadcp/Key_Components.pdf

45.

National Institute on Drug Abuse. (2012). Principles of drug addiction treatment: A research-based guide. National Institute of Health Publication. Retrieved from https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment

46.

Novak

S. P.

Bluthenthal

Wenger

Chu

Kral

A. H.

(2016). Initiation of heroin and prescription opioid pain relievers by birth cohort. American Journal of Public Health, 106, 298-300.

47.

O’Grady

C. L.

Surratt

H. L.

Kurtz

S. P.

Levi-Minzi

M. A.

(2014). Nonmedical prescription drug users in private vs. public substance abuse treatment: A cross sectional comparison of demographic and HIV risk behavior profiles. Substance Abuse Treatment Prevention Policy, 9, 1-8.

48.

Ompad

D. C.

Ikeda

R. M.

Shah

Fuller

C. M.

Bailey

et al . (2005). Childhood sexual abuse and age at initiation of injection drug use. American Journal of Public Health, 95, 703-709.

49.

Pradip

Muhuri

J. C.

Gfroerer

Davies

(2013, August). Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Retrieved from https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm

50.

Rondinelli

A. J.

Ouellet

L. J.

Strathdee

S. A.

Latka

M. H.

Hudson

S. M.

Hagan

Garfein

R. S.

(2009). Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug and Alcohol Dependence, 104, 167-174.

51.

Taxman

F. S.

Bouffard

J. A.

(2005). Treatment as part of drug court: The impact on graduation rates. Journal of Offender Rehabilitation, 42, 23-50.

52.

Teesson

Marel

Darke

Ross

Slade

Burns

. . . Mills

K. L.

(2015). Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian treatment outcome study. Addiction, 110, 986-993.

53.

Thompson

G. L.

Ammann

L. P.

(1989). Efficacies of rank transform statistics in two-way models with no interactions. Journal of the American Statistical Association, 84, 325-330.

54.

Tibshirani

(1996). Regression shrinkage and selection via the Lasso. Journal of the Royal Statistical Society, Series B, 58, 267-288.

55.

Vocci

F. J.

Schwartz

R. P.

Wilson

M. E.

Gordon

M. S.

Kinlock

T. W.

Fitzgerald

T. T.

Jaffe

J. H.

(2015). Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug and Alcohol Dependence, 1, 133-138.